Cinq thèmes sont suivis dans ce scoop.it : le libre accès (Open Access), la science citoyenne (citizen science), la science en ligne (Open Science), la science 2.0 et les cours en ligne gratuits (MOOCs).
Privacy has long been the focus of debates about how to use and disseminate data taken from human subjects during clinical research. The increasing push to share data freely and openly within biomedicine poses a challenge to the idea of private individual information, whose dissemination patients and researchers can control and monitor.
Oxford, November 22, 2012 – Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, is pleased to announce the launch of a new open access, online journal, Leukemia Research Reports.
OSDD is a CSIR led team India Consortium with global partnership with a vision to provide affordable healthcare to the developing world by providing a global platform where the best minds can collaborate & collectively endeavor to solve the complex problems associated with discovering novel therapies for neglected tropical diseases like Malaria, Tuberculosis, Leshmaniasis, etc.OSDD is a translational platform for drug discovery, bringing together informaticians, wet lab scientists, contract research organizations, clinicians, hospitals and others who are willing to adhere to the affordable healthcare philosophy. It is a concept to collaboratively aggregate the biological, genetic and chemical information available to scientists in order to use it to hasten the discovery of drugs. This will provide a unique opportunity for scientists, doctors, technocrats, students and others with diverse expertise to work for a common cause. The success of Open Source models in Information Technology (For e.g., Web Technology, The Linux Operating System) and Biotechnology (For e.g., Human Genome Sequencing) sectors highlights the urgent need to initiate a similar model in healthcare, i.e., an Open Source model for Drug Discovery.
My appeal for open access publishing to a group of the most significant US researchers for M-CM was met with some sympathy followed immediately by apologetic refusals. It is very unusual that any paper that I look up for M-CM or other related conditions is not paywalled. That said, the papers with standard per-article fees seem downright charitable compared to some that I have come across recently with $35 24-hour access fees. Perhaps those exist specifically to mock those of us without subscription access.
In 1998 GlaxoWellcome promised to set up a clinical trials register, amidst outcry over withheld trial results. But when the company merged with SKB to create GSK, in 2002, this register was unceremonially deleted from the internet. This tragic story is described in an excellent open access article on this history of attempts to get access to hidden data, by Iain Chalmers.
The BMJ's open data campaign aims to achieve appropriate and necessary independent scrutiny of data from clinical trials. Working with others, we seek to highlight the problems caused by lack of access to data, and we welcome any suggestions on how to take things further. Send a rapid response, read the Tamiflu story and correspondence below, or see all BMJ investigations.
Do the current ethical and legal policies applicable to research with genomic databases sufficiently account for the new reality of open biotechnology? How could the current policy framework be improved to facilitate the transition to a more transparent, collaborative research context? Our research will investigate the impact of open biotechnology on research ethics and legal policies with a particular focus placed on informed consent (scope of consent, privacy, data ownership) to large open database projects. We will use a combination of quantitative and qualitative research strategies that will offer complementary applied legal and ethical data on the impact of open biotechnology on the governance of genomic research. The use of a common research methodology in all streams of the project will facilitate comparisons and integration of our results. Our methods will include comparative legal and ethical research (policy review, legal research), questionnaire analysis and focus group interviews. To validate our findings, we will engage stakeholders at the annual meetings of two major organizations involved in research with open databases: The Public Population Project in Genomics (P3G) and the International Cancer Genome Consortium (ICGC).
BioMed Central, an open access journal publisher in biology and medicine, hosted the 3rd Open Access Africa conference at the University of Cape Town from 4-5 November 2012. Day 1 was well attended with over 100 participants from all parts of Africa and abroad, including funders, publishers, researchers and other interested open access advocates. Publishing Director Deborah Kahn gave an interesting overview of the state of open access and plans for the future at BioMed Central.
This blog talks about the links that can be made between tools and methods used in academia and those in public open data and how the two worlds can learn from each other in order to promote greater use and re-use of data, track impact and make...
Hoboken, N.J., November 5, 2012. John Wiley & Sons, Inc., today announced the launch of Molecular Genetics & Genomic Medicine (MGGM), a new Wiley Open Access journal. Under the leadership of Editor-in-Chief Dr. Maximilian Muenke, the journal will provide rapid dissemination of high-quality research in all areas of human, medical and molecular genetics.
Sharing your scoops to your social media accounts is a must to distribute your curated content. Not only will it drive traffic and leads through your content, but it will help show your expertise with your followers.
How to integrate my topics' content to my website?
Integrating your curated content to your website or blog will allow you to increase your website visitors’ engagement, boost SEO and acquire new visitors. By redirecting your social media traffic to your website, Scoop.it will also help you generate more qualified traffic and leads from your curation work.
Distributing your curated content through a newsletter is a great way to nurture and engage your email subscribers will developing your traffic and visibility.
Creating engaging newsletters with your curated content is really easy.